About Us

Latest News

  • May 08, 2013

    ApoPharma Celebrates International Thalassemia Day

    Today, with its partners and patient associations around the world, ApoPharma is celebrating International Thalassemia Day. This day is an opportunity to recognize Thalassemia patients who live every day with this chronic disease. A specially designed logo with the words, “Hands Across the World” was reproduced on golf shirts and distributed to all ApoPharma employees, its partners and patient associations. They are being worn today in solidarity and support of the patients who live with this condition every day. In addition, informational displays are being set up and celebrations are being held in an effort to educate people on Thalassemia. Every year the Thalassemia International Federation (TIF) chooses a theme for this special day. This year TIF is bringing to the forefront the treatment around thalassemia intermedia and is inviting all national thalassemia associations across the world and other patient support groups to find out more about this disease, within the theme: “The right for quality health care of every patient with thalassemia major and beyond.”

  • May 07, 2013

    ApoPharma supports additional research into the use of Ferriprox in children.

    Deferiprone Evaluation in Paediatrics, or DEEP, grew out of the PDCO’s (The Paediatric Committee of the European Medicines Agency) inclusion of deferiprone on the 2009 Priority Drug List. The goal is to investigate and provide data on the pharmacokinetics, efficacy and safety in children from 2 to ten years. ApoPharma has developed a new formulation specifically designed for young children. DEEP is a four-year project, and in addition to ApoPharma, the DEEP Consortium is composed of recruiting Centres from both Europe and non-European countries, along with scientific partners from the EU. DEEP is funded by the European Framework 7 Programme Recruitment for DEEP began in 2012.

    For more information of DEEP follow the link to the DEEP website: http://deep.cvbf.net

  • May 07, 2013

    ApoPharma throws support behind research into an ultra orphan indication in neurodegeneration.

    Treat Iron-Related Childhood-Onset Neurodegeneration, or TIRCON, is focused on developing a structured network to improve diagnosis and treatment of rare, inherited movement disorders. Falling under the umbrella known as Neurodegeneration with Brain Iron Accumulation (NBIA), these disorders – PKAN being the most common - usually begin in childhood, are relentlessly progressive and cause severe disability, eventually leading to premature death. TIRCON brings together, for the first time, innovative companies, an international group of scientists and clinicians, and patient representatives, all in a collaborative research environment. , TIRCON has several objectives, including the establishment of a patient registry and the conduct of a randomized, placebo-controlled study of deferiprone in patients with PKAN in both Europe and the USA. TIRCON is funded by the European Framework 7 Programme.

    For more information of TIRCON follow the link to the TIRCON website: http://tircon.eu

  • October 14, 2011

    FDA approves Ferriprox® to treat patients with excess iron in the body

    The U.S. Food and Drug Administration today approved Ferriprox®* (deferiprone) to treat patients with iron overload due to blood transfusions in patients with thalassemia, a genetic blood disorder that causes anemia, who had an inadequate response to prior chelation therapy.

    Patients with thalassemia have excess iron in the body from the frequent blood transfusions (transfusional iron overload), a condition that is serious and can be fatal. These patients also have a risk of developing liver disease, diabetes, arthritis, heart failure or an abnormal heart rhythm.

    The standard of care to treat transfusional iron overload is chelation therapy – chemical agents that are used to remove heavy metals from the body. Ferriprox is intended for use when chelation therapy is inadequate.

    "Ferriprox represents the first new FDA-approved treatment for this disorder since 2005," said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research...Read More

Leaving ApoPharma.com

You are now leaving ApoPharma Inc. This link will take you to a web site where this site’s Privacy Policy does not apply. You are solely responsible for your interactions with that web site. We encourage you to read the privacy policy of every Web site you visit.

CONTINUE RETURN TO APOPHARMA.COM

Leaving ApoPharma.com

You have expressed an interest in looking at job openings for ApoPharma Inc. You are now leaving the ApoPharma website and entering the Apotex website. Do not be concerned, ApoPharma is a part of the Apotex group of companies. All job openings for Apotex member companies, including those for ApoPharma Inc. are found on this website.

CONTINUE RETURN TO APOPHARMA.COM